Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK C NAPOLI

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1811984537
CMS profile
218049
Location
MONROE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,208.29

158 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,208.29 158

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK C NAPOLI

NPI 1811984537 · CMS profile ID 218049

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

MONROE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811984537?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK C NAPOLI, NPI 1811984537, CMS profile ID 218049. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811984537?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARK C NAPOLI, NPI 1811984537, CMS profile ID 218049. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811984537?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARK C NAPOLI, NPI 1811984537, CMS profile ID 218049, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1811984537?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

158 matching records · $2,208.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 158 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 158.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $17.8409/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843573603 CMS
E.R. Squibb & Sons, L.L.C. $13.2509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783592129 CMS
Amgen Inc. $3.9609/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585183 CMS
Janssen Pharmaceuticals, Inc $10.3209/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712453 CMS
Kowa Pharmaceuticals America, Inc. $17.9308/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805540923 CMS
Actelion Pharmaceuticals US, Inc. $19.4608/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712483 CMS
SANOFI-AVENTIS U.S. LLC $16.8408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843573601 CMS
Novartis Pharmaceuticals Corporation $18.9908/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110777 CMS
Amgen Inc. $4.0708/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585179 CMS
Amarin Pharma Inc. $10.8508/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815056201 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.0108/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763347444 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.4808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768809242 CMS
Janssen Pharmaceuticals, Inc $11.2508/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712459 CMS
Amgen Inc. $19.6407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585175 CMS
Actelion Pharmaceuticals US, Inc. $17.6407/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712475 CMS
Esperion Therapeutics, Inc. $13.5007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360977 CMS
PFIZER INC. $16.5107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832678747 CMS
Novartis Pharmaceuticals Corporation $4.7407/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110773 CMS
Amarin Pharma Inc. $9.9907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815281203 CMS
Amgen Inc. $3.7407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585171 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.2207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763347446 CMS
Janssen Pharmaceuticals, Inc $11.8407/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712439 CMS
Novartis Pharmaceuticals Corporation $12.9607/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110761 CMS
Novartis Pharmaceuticals Corporation $2.8107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110769 CMS
Novartis Pharmaceuticals Corporation $12.5207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110757 CMS
Actelion Pharmaceuticals US, Inc. $16.8607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712485 CMS
Amgen Inc. $4.2907/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585167 CMS
Kowa Pharmaceuticals America, Inc. $27.4706/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805540917 CMS
Janssen Pharmaceuticals, Inc $12.7006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712443 CMS
Janssen Pharmaceuticals, Inc $12.1806/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712441 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $15.0006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768784116 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5606/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763347448 CMS
Esperion Therapeutics, Inc. $15.0006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360973 CMS
Merck Sharp & Dohme Corporation $19.0006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848712059 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.1006/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768784114 CMS
Amgen Inc. $3.9806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585163 CMS
Actelion Pharmaceuticals US, Inc. $13.5806/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712479 CMS
Janssen Pharmaceuticals, Inc $20.2606/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712473 CMS
Esperion Therapeutics, Inc. $11.7906/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838360971 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $15.9406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768784112 CMS
PFIZER INC. $20.7206/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833530063 CMS
Amgen Inc. $3.9806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585159 CMS
SANOFI-AVENTIS U.S. LLC $14.2706/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843573577 CMS
Amgen Inc. $3.5306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585155 CMS
Actelion Pharmaceuticals US, Inc. $18.1606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712477 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.1506/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768784110 CMS
Janssen Pharmaceuticals, Inc $0.6805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712427 CMS
Janssen Pharmaceuticals, Inc $13.5105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788712429 CMS
PFIZER INC. $15.1205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832621605 CMS
Amgen Inc. $15.5605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825585151 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,181.24 113
PY2020 $1,640.98 95
PY2021 $2,208.29 158
PY2022 $1,839.16 108
PY2023 $1,705.63 87
PY2024 $2,691.31 87
PY2025 $1,245.31 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $602,925.17 45
PY2024 Recipient $128,757.31 3
PY2024 Principal investigator $371,622.18 32
PY2023 Principal investigator $162,612.42 16
PY2022 Principal investigator $229,727.07 16
PY2021 Principal investigator $185,958.04 205
PY2020 Principal investigator $264,876.30 109
PY2019 Principal investigator $386,007.62 205

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,465.01 12/31/2025 Non-covered Recipient Entity
IMA Clinical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920077
Principal investigator 1 Janssen Research & Development, LLC $3,995.00 12/24/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255126
Principal investigator 1 Eli Lilly and Company $65.70 12/17/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187881918
Principal investigator 1 Janssen Research & Development, LLC $1,626.00 12/12/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255239
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770163
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,371.20 11/24/2025 Non-covered Recipient Entity
IM Super Holdings LLC dba IMA Evaluations LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220806005
Principal investigator 1 Janssen Research & Development, LLC $4,023.00 11/19/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255214
Principal investigator 1 Merck Sharp & Dohme LLC $14,502.50 11/14/2025 Non-covered Recipient Entity
IMA Clinical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920802
Principal investigator 1 Janssen Research & Development, LLC $4,878.00 11/07/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255231
Principal investigator 1 Janssen Research & Development, LLC $400.00 11/03/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255197
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770161
Principal investigator 1 Janssen Research & Development, LLC $242.00 10/08/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255096
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770159
Principal investigator 1 Janssen Research & Development, LLC $1,291.00 09/19/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255157
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770153
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/29/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998407
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770155
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770157
Principal investigator 1 Janssen Research & Development, LLC $1,291.00 08/25/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255266
Principal investigator 1 Amgen Inc. $82,191.60 08/23/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC DBA IMA CLINICAL RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246642517
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 08/14/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815033
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770145
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770147
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770149
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Ima Clinical Research Monroe
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770151
Principal investigator 1 Janssen Research & Development, LLC $121.00 07/25/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255250
Principal investigator 1 Janssen Research & Development, LLC $450.00 07/11/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255332
Principal investigator 1 Janssen Research & Development, LLC $310.00 07/07/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255283
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,331.02 06/30/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF AMERICA
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308536
Principal investigator 1 Janssen Research & Development, LLC $968.00 06/26/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255223
Principal investigator 1 Amgen Inc. $5,641.41 06/24/2025 Non-covered Recipient Entity
IMA CLINICAL RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246642566
Principal investigator 1 Janssen Research & Development, LLC $5,600.00 06/20/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255188
Principal investigator 1 Janssen Research & Development, LLC $605.00 06/09/2025 Non-covered Recipient Entity
The Ima Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175255298
Principal investigator 1 Janssen Research & Development, LLC $340.00 05/19/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224236
Principal investigator 1 PFIZER INC. $4,253.56 04/26/2025 Non-covered Recipient Entity
Clinical Trials of America LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228779003
Principal investigator 1 Janssen Research & Development, LLC $6,952.00 03/21/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224177
Principal investigator 1 Janssen Research & Development, LLC $5,148.00 03/14/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224265
Principal investigator 1 Eli Lilly and Company $220.00 03/05/2025 Non-covered Recipient Entity
LOUISVILLE METABOLIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187885746
Principal investigator 1 Janssen Research & Development, LLC $11,873.00 02/19/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224213
Principal investigator 1 Janssen Research & Development, LLC $185.00 02/05/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224257
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,631.00 01/30/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF AMERICA
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310572
Principal investigator 1 Eli Lilly and Company $5,845.75 01/27/2025 Non-covered Recipient Entity
MEDEX HEALTHCARE RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886812
Principal investigator 1 Amgen Inc. $20,584.51 01/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS OF AMERICA LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640381
Principal investigator 1 Janssen Research & Development, LLC $3,118.00 01/22/2025 Non-covered Recipient Entity
Clnc Trials Of America, Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175224228
Principal investigator 1 Eli Lilly and Company $347,523.00 01/06/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187881460